RECENT FUNDING
  1. Recent Funding
  2. Investors
  3. CITA Investissement
C

CITA Investissement portfolio

CITA Investissement has 1 portfolio company on record at Recent Funding.

Website: cita-invest.com.
Type: Private equity.
Portfolio on Recent Funding: 1.
Deals, last 12 months: 0.
Capital in their rounds: $32.67M.
Latest deal: UroMems · May 20, 2020.
About this page

It is a private equity firm based in Paris, FR, founded in 1985. Its most recent investment on record is UroMems's $17.6M Series B+ round in May 2020, alongside Wellington Management, b2venture, Bpifrance and 3 others. That company is in Health and bio. It has co-invested with Wellington Management, Bpifrance and b2venture, most often Wellington Management (2 rounds).

About CITA Investissement

Firm type: Private equity.
Headquarters: Paris, FR.
Founded: 1985.
Stages: Seed, Series A, Growth.
Sectors: Retail Tech, SaaS, Sector Agnostic.
Check size: $1.08M to $16M.
Leads rounds: No.

What CITA Investissement invests in

How CITA Investissement invests

StageDealsCapital in rounds
Series A 1 50%$15.07M
Series B+ 1 50%$17.6M
YearDealsCapital in rounds
2016 1 50%$15.07M
2020 1 50%$17.6M

CITA Investissement portfolio companies

CompanyRound with CITA InvestissementTotal raisedLatest raise
UUroMems
Health and bio
Series B+ · $17.6M$139.67MMay 13, 2026
round

Most frequent co-investors

Similar investors

Investors whose portfolios on Recent Funding center on the same category (Health and bio).

How this is counted

Firm profile: Fundraising Fox Open Dataset v2026-11, CC BY 4.0. Track-record counts are theirs, not Recent Funding's.

Share is of the 2 rounds on Recent Funding that name CITA Investissement. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.

Portfolio companies are the companies on Recent Funding with a round that lists CITA Investissement, which is a subset of its real portfolio. API: /api/v1/investors/cita-investissement (get a free API key). More: the most active VC firms and new venture capital funds.